Skip to content

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06446453
Enrollment
52
Registered
2024-06-06
Start date
2024-06-25
Completion date
2027-06-01
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Units, Neonatal, Pulmonary Surfactants, Respiratory Distress Syndrome, Newborn

Brief summary

Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier surfactant therapy and may improve short-term respiratory outcomes. This study will test this theory by comparing lung ultrasound score-guided surfactant therapy for premature infants with RDS with our current surfactant administration guidelines.

Interventions

DIAGNOSTIC_TESTEchography-guided Surfactant THERapy (ESTHER)

Decision to administer surfactant therapy using a semi-quantitative lung ultrasound score.

Sponsors

Connecticut Children's Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 2 Years
Healthy volunteers
No

Inclusion criteria

* The infant's parent/legal guardian can understand and willingly sign a written informed consent document for this study * Birth gestational age between 27w0d-36w6d * Diagnosis of respiratory failure secondary to RDS requiring respiratory support with non-invasive positive pressure ventilation

Exclusion criteria

* Unable to obtain lung ultrasound between 1-2 hours of life * Infants already intubated or received surfactant before the point of care lung ultrasound * Infants born with congenital cardiac disease, congenital lung disease, or congenital facial/airway malformations * Infants born with chromosomal abnormalities * Infants with APGARs ≤ 5 at 10 minutes of life * Infants requiring cardiopulmonary resuscitation or therapeutic hypothermia in the first 6 hours of life

Design outcomes

Primary

MeasureTime frameDescription
Oxygen Saturation IndexAt 24 hours of life.(CPAP Level x FiO2)/(SpO2)

Secondary

MeasureTime frameDescription
Oxygen Saturation IndexAt 48 and 72 hours of life.(CPAP Level x FiO2)/(SpO2)

Countries

United States

Contacts

CONTACTJacob Kelner
jkelner@connecticutchildrens.org860-545-9720
PRINCIPAL_INVESTIGATORJacob Kelner

Connecticut Children's

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026